Perseus Proteomics Inc.
JPX: 4882.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Takuya Yokokawa
- Employees
- 25
- Headquarters
- Tokyo, Japan
- IPO year
- 2021
- Market cap
- ¥3.2B
- Website
- https://www.ppmx.com
Loading 4882…
Loading profile data…Frequently asked questions about 4882
What does Perseus Proteomics Inc. (4882.T) do?
Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activit...
Where does 4882.T trade?
Perseus Proteomics Inc. (4882.T) trades on the Tokyo Stock Exchange.
What sector is 4882.T in?
Perseus Proteomics Inc. (4882.T) operates in the Healthcare sector, specifically in the Drug Manufacturers - General industry.
Who is the CEO of Perseus Proteomics Inc.?
Takuya Yokokawa is the chief executive officer of Perseus Proteomics Inc. (4882.T).
Where is Perseus Proteomics Inc. headquartered?
Perseus Proteomics Inc. is headquartered in Japan.
Does 4882.T pay a dividend?
Perseus Proteomics Inc. (4882.T) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 4882.T go public?
Perseus Proteomics Inc. (4882.T) completed its initial public offering in 2021.